Correction of insulin resistance in patients with chronic obstructive pulmonary disease under the influence of recovery treatment
DOI:
https://doi.org/10.26641/2307-0404.2023.4.294220Keywords:
COPD, іnsulin resistance, COVID-19, recovery treatment, haloaerosoltherapyAbstract
According to modern concepts chronic obstructive pulmonary disease (COPD) is accompanied by persistent respiratory symptoms, as well as extrapulmonary systemic manifestations. Insulin resistance and metabolic syndrome belong to the leading causes of comorbidity formation. The aim is to study the possibilities of insulin resistance correction in COPD patients, taking into account the previous COVID-19, under the influence of complex non-pharmacological treatment based on haloaerosoltherapy in connection with the applied treatment complex. Clinical and functional examinations and carbohydrate metabolism investigations were carried out in 115 patients with COPD (GOLD II-III) beyond the acute period before and after the course of recovery treatment. Among them 60 patients were convalescents after COVID-19. The average age of patients was 60,3±1,71 years and duration of COPD – 14,2±0,89 years. A control group 12 practically healthy persons were also examined. The presence of insulin resistance was diagnosed by evaluation of the glucose, insulin, HOMA-IR index and C-peptide levels. Treatment was carried out according to three treatment complexes. The main component of the treatment was the use of haloaerosoltherapy and its combination with singlet oxygen therapy or drinking and inhalation of mineral water. The duration of the course of treatment was 20-21 days. Before treatment the presence of insulin resistance was confirmed in both groups of patients with COPD (without COVID-19 and convalescents after COVID-19). Blood glucose levels were significantly higher in the latter group. After the course of recovery treatment a decrease in insulin resistance was noted, especially in patients who received complex treatment, although complete normalization of the studied indices was not achieved. Thus, insulin resistance is a characteristic, pathogenetically determined metabolic manifestation in COPD, which requires constant monitoring and development of long-term programs of complex clinical management of this contingent of patients, especially beyond the exacerbation period. The use of haloaerosoltherapy, which has a sanative and anti-inflammatory effect and promotes clinical stabilization of COPD, is accompanied by a decrease in the manifestations of insulin resistance. Expressiveness of these changes depend on the applied treatment complex. The most pronounced decrease in insulin resistance in COPD patients was noted in a complex treatment based on haloaerosoltherapy with additional drinking and inhalation use of low-mineralized hydrocarbonate siliceous mineral water.
References
Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (2022 report) [Internet]. [cited 2023 Jan 10]. Available from: https://goldcopd.org/wp-content/uploads/2021/12/GOLD-REPORT-2022-v1.1-22Nov2021_WMV.pdf
Zhou W, Li C, Cao J, Feng J. Metabolic syndrome prevalence in patients with obstructive sleep apnea syndrome and chronic obstructive pulmonary disease: Relationship with systemic inflammation. Clin Respir J. 2020;14(12):1159-65. doi: https://doi.org/10.1111/crj.13253
Vantyukh NV, Lemko ОІ. [Some aspects of in-sulin resistance formation in chronic obstructive pulmo-nary disease]. Problems of Endocrine Pathology. 2022;79(1):51-6. Ukrainian. doi: https://doi.org/10.21856/j-PEP.2022.1.07
Zuberi FF, Bader N, Rasheed T, Zuberi BF. Association between insulin resistance and BMI with FEV1 in non-hypoxemic COPD out-patients. The clinical respi-ratory journal. 2021;15(5):513-21. doi: https://doi.org/10.1111/crj.13336
Ruan W, Yan C, Zhu H, et al. Downregulated level of insulin in COPD patients during AE: role beyond glucose control? Int J Chron Obstruct Pulmon Dis. 2019;(14):1559-66. doi: https://doi.org/10.2147/COPD.S197164
Dogra M, Jaggi S, Aggarwal D, et al. Role of interleukin-6 and insulin resistance as screening markers for metabolic syndrome in patients of chronic obstructive pulmonary disease. A hospital-based cross-sectional study. Monaldi archives for chest disease = Archivio Monal-di per le malattie del torace. 2022;92(3):10.4081.6p. doi: https://doi.org/10.4081/monaldi.2021.2024
Machado FVC, Pitta F, Hernandes NA, Bertolini GL. Physiopathological relationship between chronic obstructive pulmonary disease and insulin resistance. Endocrine. 2018;61(1):17-22. doi: https://doi.org/10.1007/s12020-018-1554-z
Gómez Antúnez M, Muiño Míguez A, et al. Clinical Characteristics and Prognosis of COPD Patients Hospitalized with SARS-CoV-2. Int J Chron Obstruct Pulmon Dis. 2021;5:3433-45. doi: https://doi.org/10.2147/COPD.S276692
Reiterer M, Rajan M, Gomez-Banoy N, et al. Hyperglycemia in acute COVID-19 is characterized by insulin resistance and adipose tissue infectivity by SARS-CoV-2. Cell Metabolism. 2021;33(12):2174-88. doi: https://doi.org/10.1016/j.cmet.2021.10.014
Feshchenko YuI, Iashyna LA, Opimakh SG, et al. [Features of lung impairment due to COVID-19 in patients of the first wave of the pandemic (literature review)]. Medicni perspektivi. 2022;27(4):20-6. Ukrainian. doi: https://doi.org/10.26641/2307-0404.2022.4.271118
Malik JA, Ahmed S, Shinde M, et al. The impact of COVID-19 on comorbidities: a review of recent updates for combating it. Saudi J Biol Sci. 2022;29(5):3586-99. doi: https://doi.org/10.1016/j.sjbs.2022.02.006
Lemko O, Lemko I. Haloaerosoltherapy: mechanisms of curative effect and place in the respiratory rehabi¬litation. Balneo and PRM Research Journal. 2021;12(4):365-75. doi: https://doi.org/10.12680/balneo.2021.464
Lemko OI. Artificial analogies of speleotherapy and their medical use. In: Techniques&Society: Pro¬cee-dings of the 18th Congress of Speleology. [Internet]. Sa-voie Mont Blanc; 2022 [cited 2023 Jan 10];6:365-8. Available from: https://uis-speleo.org/wp-content/up-loads/2022/09/ACTES_CONGRES_UIS_WEB_VOLUME_6.pdf
Lemko OI, Vantiukh NV, Reshetar DV. [Possibi-lities of haloaerosoltherapy as respiratory rehabilitation in the correction of insulinresistance in patients with chronic obstructive pulmonary disease]. Ukr Pulmonol J. 2023;31(1):66-71. Ukrainian. doi: https://doi.org/10.31215/2306-4927-2023-31-1-66-71
Antuna-Puente B, Disse E, Rabasa-Lhoret R, et al. How can we measure insulin sensitivity/resistance? Diabetes & Metabolism. 2011;37(3):179-88. doi: https://doi.org/10.1016/j.diabet.2011.01.002
Antomonov MYu. [Mathematical processing and analysis of medical and biological data]. 2nd ed. Kyiv: Medinform; 2017. 578 p. Russian.
Bird SR, Hawley JA. Update on the effects of physical activity on insulin sensitivity in humans. BMJ Open Sport Exerc Med. 2017;2(1):e000143. doi: https://doi.org/10.1136/bmjsem-2016-000143
Kumar AS, Maiya AG, Shastry BA, et al. Exercise and insulin resistance in type 2 diabetes mel¬litus: A systematic review and meta-analysis. Annals of Physical and Rehabilitation Medicine. 2019;62:98-103. doi: https://doi.org/10.1016/j.rehab.2018.11.001
Lemko OI, Lemko IS, Haysak MO. Halotherapy, haloaerosoltherapy: Science and practice. In: Science of Sea Salt: Benefits of Human Health. Dallas, Texas, USA: Taylor Specialty Books, Content Lead: Rajiv Saini; 2022. 243-64 p.
Uysal B, Ulusinan E. The Importance of Halotherapy in the Treatment of COVID-19 Related Diseases. J Clin Exp Invest. 2020;11(4):em00754.7p. doi: https://doi.org/10.29333/jcei/8486
Zabolotna IB, Gushcha SG, Mikhailenko VL. Non-alcoholic fatty liver disease and mineral waters of Ukraine – opportunities of application (experimental-clinical studies). Balneo Research Jornal. 2018;9(3):270-6. doi: http://dx.doi.org/10.12680/balneo.2018.194
Lemko IS, Haysak MO, Dychka LV. Quantitative evaluation of alkalinizing features of natural mineral waters of Transcarpathia. Balneo Research Journal. 2020;11(2):174-9. doi: http://doi.org/10.12680/balneo.2020.336
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Medicni perspektivi
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submitting manuscript to the journal "Medicni perspektivi" the author(s) agree with transferring copyright from the author(s) to publisher (including photos, figures, tables, etc.) editor, reproducing materials of the manuscript in the journal, Internet, translation into other languages, export and import of the issue with the author’s article, spreading without limitation of their period of validity both on the territory of Ukraine and other countries. This and other mutual duties of the author and all co-authors separately and editorial board are secured by written agreement by special form to use the article, the sample of which is presented on the site.
Author signs a written agreement and sends it to Editorial Board simultaneously with submission of the manuscript.
